Cell-free DNA From Junction of Hepatitis B Virus Integration in HCC Patients for Monitoring Post-resection Recurrence

NCT05823584 | Completed

• 1 other identifier: ctDNA-HCC-01
• Study Type: observational
• Target: 207
• Locations: 1 country
• Sites: 1

Brief Summary

HBV DNA integration has been found in the chromosomes of about 90% of HBV-related HCC and the integration site is unique to individual HCC. The virus-host chimera DNA (vh-DNA) from HBV integration sites in HCC a reliable evidence even in the patient with a tiny tumor which is not large enough to be detected by the image scan. The goal of this observational study is to compare the prediction ability of vh-DNA with the other biomarkers for monitoring the recurrent of HBV-related HCC. The main questions that aim to answer are the sensitivity and specificity of vh-DNA/AFP/ALP-L3/PIVKA-II/TERTC2280 when the gold standard is the guideline of HCC diagnosis. The surgical tissues and plasma samples from the participants would be collected undergoing the HCC recession surgery when joining the study at the beginning, in order to identify the HBV integration in tumor by Capture NGS and quantify the specific vh-DNA in plasma by ddPCR as personalized biomarkers for minimal residual disease (MRD) monitoring. Moreover, the consistency of vh-DNA from tumor will be validated by pre-operative plasma. Then the participants will be asked to performed the visit at 2, 5, 8, 11, 14 months after the HCC recession surgery. The plasma sample for vh-DNA/AFP/ AFP-L3/ PIVKA-II/ TERTp C228T testing and the image data from ultrasound, CT or MRI would also be collected at these visits. When the vh-DNA testing result is positive and there is no recurrence at 14 months after the HCC recession surgery, some participants will be asked to followed at 17, 20 months. Researcher will compare the sensitivity, specificity and predict day of vh-DNA with AFP/ AFP-L3/ PIVKA-II/ TERTp C228T as a biomarker for HCC surveillance. The true value of this novel HBV chimera vh-DNA will be revealed. The results will also support to use for monitoring post-operative recurrence. In addition, the investigators will explore the performance of TERTp C228T mutation from non-HBV HCC patients. As a different target of ctDNA for HCC, TERTp C228T will be identified using surgical tissues from HCC patients, and plasma samples from the same patient before/after operation will be tested by ddPCR . It will be evaluated that TERTp C228T is predictive or not for recurrence monitoring of HCC.

Conditions

Hepatocellular Carcinoma

Keywords

Hepatocellular Carcinoma; Hepatitis b Virus; Biomarker; Cell-free DNA; cfDNA; Circulating tumor DNA; ctDNA; virus-host chimera DNA; Chimera DNA

Outcome Measures

Primary Outcomes (1)

• Sensitivity (vh-DNA vs AFP) (the vh-DNA which could be detected in the pre-operative plasma of participants.)

  Compare the sensitivity of vh-DNA with AFP as a biomarker for HCC surveillance.

  HCC recurrence within 14 months of post-operative.

Secondary Outcomes (6)

• Sensitivity (vh-DNA vs AFP) (the vh-DNA which could not be detected in the pre-operative plasma of participants.)

  HCC recurrence within 14 months of post-operative.

• Sensitivity (vh-DNA vs AFP-L3/PIVKA-II/TERTp C228T)

  HCC recurrence within 14 months of post-operative.

• Specificity (vh-DNA vs AFP/AFP-L3/PIVKA-II/TERTp C228T)

  The 14 months of post-operative.

• Predicted days (vh-DNA vs AFP/AFP-L3/PIVKA-II/TERTp C228T)

  HCC recurrence within 14 months of post-operative.

• Clonality

  HCC recurrence within 14 months of post-operative.

Eligibility Criteria

• Age: 20 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The patients with HCC are scheduled to undergo hepatic resection or liver transplant.

You may qualify if:

• ≥20 years old.
• Subject who is diagnosed with HCC
• Subject who is scheduled to undergo hepatic resection or liver transplant.

You may not qualify if:

• Subject who should not treat with the contrast media (for imaging)
• Active malignancy (still under intensive cancer treatment or considered in progression) or disease free interval less than one year before entering the study.

Sponsors & Collaborators

• TCM Biotech International Corp.: lead
• National Taiwan University Hospital: collaborator

Study Sites (1)

National Taiwan University Hospital

Taipei, Taiwan

Location

Biospecimen

Retention: SAMPLES WITH DNA

Plasma、Tissue、ctDNA

MeSH Terms

Conditions

Carcinoma, Hepatocellular; Hepatitis B

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases; Blood-Borne Infections; Communicable Diseases; Infections; Hepadnaviridae Infections; DNA Virus Infections; Virus Diseases; Hepatitis, Viral, Human; Hepatitis

Study Officials

• Pei-Jer Chen, Ph.D

  National Taiwan University Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 10, 2023
• First Posted: April 21, 2023
• Study Start: December 22, 2019
• Primary Completion: July 21, 2023
• Study Completion: December 31, 2023
• Last Updated: April 10, 2024

Record last verified: 2023-10

Data Sharing

• IPD Sharing: Will not share

Locations

TW (1)